Compare Medpace Holdings Inc (MEDP) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Ralph Lauren Corp — how do they compare? Medpace Holdings Inc trades at $530.22 (market cap $15.08B), while Ralph Lauren Corp trades at $375.67 (market cap $22.41B). The key difference: Ralph Lauren Corp is the larger of the two by market cap, and Ralph Lauren Corp pays a 0.99% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | RL | |
|---|---|---|
Market Cap | $15.08B | $22.41B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $414.25 |
52-Week Low | $308.88 | $283.34 |
Enterprise Value | $14.55B | $23.35B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Ralph Lauren (RL) trades at $376.55, down 1.03% on the day, with a neutral technical signal and key support at $370. The company demonstrates strong fundamentals, with revenue growing to $7.08B in 2025 and net income of $742.9M, supported by a 69.87% gross margin and consistent earnings beats. Analyst consensus is bullish with a $445.71 price target, and recent news highlights brand strength and digital expansion.
The outlook for RL is positive, driven by earnings momentum and strategic initiatives, though premium valuation and market volatility present risks. Upside potential exists if the company maintains its growth trajectory and meets Q2 2026 EPS expectations of $4.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
